News Detail
Mumbai, 6 April 2024: The Nashik Division of the Maharashtra Food and Drug Administration (FDA) has launched an inquiry into stickering and mislabelling practices observed on Glenmark's hypertension medication, Telma 40 and Telma 20 tab batches, produced in Sikkim.
Thi......
View Details
Source : Pharmabiz
Maharashtra FDA
stickering
mislabeling
hypertension
Telma 40
Telma 20
MRP
Activist Nadie Jauhri
Glenmark Pharmaceuticals
Competition Commission of India
CCI
Drugs and Cosmetics
D&C Act
Section 3(1)
Related News
- A drug manufacturing facility operating without license busted in Kharkhoda (25-03-2025)
- Delhi HC allows Natco to make Roche's spinal muscular atrophy drug 'Risdiplam' in public interest (25-03-2025)
- Enforce regulations, strengthen penalties to fight the menace of counterfeit drugs: Parliamentary Panel (25-03-2025)
- Supplement firm Bioventra warns of online fakes (25-03-2025)
- FDA drug approvals drops, but smaller pharma leads innovation: GlobalData (25-03-2025)
- No staff involved in promoting fake drugs, vaccination: Odisha Health Minister (25-03-2025)
- Centre to introduce standardised hospital billing format to ensure transparency (24-03-2025)
- CDSCO asks MSME pharma firms to apply online for Schedule M extension (24-03-2025)
- Father and son arrested for unlicensed medicine sales, concealed drugs in cowshed (24-03-2025)
- AI-driven device by PGI set to transform neuropathic pain diagnosis (24-03-2025)